Skip to main content
Premium Trial:

Request an Annual Quote

RXi Regains Nasdaq Listing

Premium

RXi Pharmaceuticals announced this month that its stock has once again begun trading on the Nasdaq stock market.

"Listing on Nasdaq will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders," RXi President and CEO Geert Cauwenbergh said in a statement.

RXi had previously traded on the Nasdaq but lost its listing when it merged with Apthera in 2011. The new company changed its name to Galena, took RXi’s stock listing, and made RXi a subsidiary. RXi was later spun out as a publicly traded independent company again, but traded on the over-the-counter bulletin board.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.